PLCOSKIN
PLCOSKIN is a Seoul-based regenerative medicine company that manufactures 3D-printed polycaprolactone (PCL) mesh medical devices, including TissueDerm, used in breast reconstruction and soft-tissue scaffold applications.
- CEO / Founder
- Woo-yeol Baek (백우열)
- Team Size
- 11-50
- Stage
- Growth Stage
- Total Funding
- $14.4M
- Latest Round
- Series C
- Key Investors
- SBI Investment; BNH Investment; PNK Dermatology Clinical Research Center (Daebong Group); Highlight Capital
Technology & Products
Key Products
TissueDerm / Tissuemesh BCS (PCL 3D-printed hybrid mesh for post-mastectomy breast reconstruction, MFDS Class IV approved, exported to 50+ countries); TissueDerm Orbit; TissueDerm Graft; Medi A Derm; hybrid mesh 'TissueDerm' for scar/adhesion soft-tissue scaffolding (launching at KIMES BUSAN 2026); Yourif regenerative-medicine skincare brand
Technical position · AMPulse analysis
Proprietary 3D-printed PCL/collagen hybrid mesh scaffold platform; KGMP and ISO 13485 certified; Korea MFDS Class IV device approval for TissueDerm; tunable design by body part and surgical context
Differentiation
Value Proposition
3D-printed bioresorbable PCL mesh scaffolds promote autologous tissue regeneration at surgical and scar/adhesion sites, offered as a synthetic, uniform-thickness alternative to allogeneic dermal matrix (ADM) grafts, which the company says suffer from irregular absorption, hardening, high cost, and supply constraints.
How They Differentiate
Positions its synthetic, 3D-printed PCL mesh as a lower-cost, non-immunogenic, uniformly-manufactured alternative to donor-tissue-derived ADM grafts, with design flexibility to tailor mesh geometry by body part and surgical indication
Market & Competition
Target Customers
Plastic and reconstructive surgeons, hospitals, and medical device distributors serving breast reconstruction, hernia/abdominal wall repair, burn care, and diabetic wound treatment markets
Industry Verticals
Medical devices, plastic & reconstructive surgery, breast cancer reconstruction, wound care, dermatology/skincare
Competitors
Allogeneic dermal matrix (ADM) producers such as AlloDerm (LifeCell/Allergan/AbbVie) and other human/animal-derived acellular dermal matrix makers; other synthetic soft-tissue reconstruction mesh and PCL scaffold developers in the regenerative medicine space
Growth & Milestones
Growth Metrics
~35 employees (as of 2026-07 per THE VC/National Pension registry data); 9.5 years in operation; TissueDerm/Tissuemesh BCS exported to 50+ countries
Major Milestones
2017: Founded as Yonsei University faculty startup by Dr. Woo-yeol Baek; 2020: Series A; 2023: Series B, MFDS approval for TissueDerm; 2024: CES Innovation Award for TissueDerm; 2025: Global TIPS selection, GBCC 2025 presentation of Tissuemesh BCS, Series C (₩10B, SBI Investment lead) and Series C extension ($2M, Highlight Capital); 2026: Exclusive distribution deals in Saudi Arabia/Taiwan/Mexico-Central America; TissueDerm hybrid mesh launch at KIMES BUSAN 2026; targeting 2027 KOSDAQ listing
Recent coverage of PLCOSKIN
AM patents
AM-relevant patents linked to this company.
- Patents
- 4
- Granted
- 2
- Families
- 4
Leading domains: application (4), process (4), equipment (1)
Filings by year: 2021: 1 · 2019: 3
- DEVELOPMENT OF 3D POLYMERIC HYBRID STRUCTURES FOR SUBSTITUTION OF ACELLULAR DERMAL MATRIX ON BREAST RECONSTRUCTION102214090 · KR
- NOVEL POROUS SCAFFOLD AND METHOD FOR MANUFACTURING SAME20220347351 · US
- 3-Dimensional Biocompatible Structure for Tissue Repair20230103926 · KR
- NOVEL POROUS SCAFFOLD AND METHOD FOR MANUFACTURING SAME20260000812 · US